维格列汀-话题@MedSci

#维格列汀#

9篇内容 | 1152人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2210532, encodeId=947b22105323b, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a> <a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a> <a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=25f0115659e5' target=_blank style='color:#2F92EE;'>#瑞格列净#</a>, objectTitle=JTUMS：维格列汀和瑞格列净联合二甲双胍治疗2型糖尿病的疗效和安全性, objectType=article, longId=830499, objectId=503a8304996d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240618/1718704635088_92910.jpg, objectUrl=/article/show_article.do?id=503a8304996d, replyNumber=0, likeNumber=110, createdTime=2024-06-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=503a8304996d, moduleTitle=JTUMS：维格列汀和瑞格列净联合二甲双胍治疗2型糖尿病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=503a8304996d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1677525, encodeId=748516e7525a9, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=.JACC Heart Failure:维格列汀对2型糖尿病合并心衰患者心室功能有何影响？, objectType=article, longId=126966, objectId=e3ef1269661c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3ef1269661c, replyNumber=0, likeNumber=75, createdTime=2018-08-07, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3ef1269661c, moduleTitle=.JACC Heart Failure:维格列汀对2型糖尿病合并心衰患者心室功能有何影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3ef1269661c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677524, encodeId=59f416e752418, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=Diabetes Care：维格列汀和二甲双胍对小肠输注葡萄糖的2型糖尿病患者血压和心率的反应有啥影响？, objectType=article, longId=90986, objectId=2d629098630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d629098630, replyNumber=0, likeNumber=66, createdTime=2017-09-25, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d629098630, moduleTitle=Diabetes Care：维格列汀和二甲双胍对小肠输注葡萄糖的2型糖尿病患者血压和心率的反应有啥影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d629098630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677523, encodeId=a58c16e7523b2, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=母义明：维格列汀是2型糖尿病单药治疗后的又一选择？, objectType=article, longId=51345, objectId=0c1451345e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c1451345e1, replyNumber=0, likeNumber=70, createdTime=2015-12-25, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c1451345e1, moduleTitle=母义明：维格列汀是2型糖尿病单药治疗后的又一选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c1451345e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677522, encodeId=4bc416e752212, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=诺华提请禁止印度百康推出其维格列汀仿制药, objectType=article, longId=33255, objectId=4d633325514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d633325514, replyNumber=0, likeNumber=85, createdTime=2014-10-16, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d633325514, moduleTitle=诺华提请禁止印度百康推出其维格列汀仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d633325514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677521, encodeId=c65616e752144, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=Lancet: 维格列汀首证个体化达标在老年糖尿病患者中可以实现（INTERVAL研究）, objectType=article, longId=20956, objectId=e3702095606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3702095606, replyNumber=0, likeNumber=124, createdTime=2014-04-27, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3702095606, moduleTitle=Lancet: 维格列汀首证个体化达标在老年糖尿病患者中可以实现（INTERVAL研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3702095606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677520, encodeId=f4f116e75202e, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=Medpage：维格列汀对心力衰竭患者的心血管安全性尚不确定, objectType=article, longId=19862, objectId=c62f19862c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62f19862c8, replyNumber=0, likeNumber=130, createdTime=2013-11-30, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62f19862c8, moduleTitle=Medpage：维格列汀对心力衰竭患者的心血管安全性尚不确定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62f19862c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677519, encodeId=bc4816e75196c, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=诺华维格列汀（佳维乐）在中国上市, objectType=article, longId=4089, objectId=b10640893f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b10640893f, replyNumber=0, likeNumber=132, createdTime=2012-04-22, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b10640893f, moduleTitle=诺华维格列汀（佳维乐）在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b10640893f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677518, encodeId=f15916e751848, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=JCPT：Meta分析证实维格列汀疗效和安全性, objectType=article, longId=3623, objectId=462736233c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=462736233c, replyNumber=0, likeNumber=123, createdTime=2012-03-20, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=462736233c, moduleTitle=JCPT：Meta分析证实维格列汀疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=462736233c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677517, encodeId=fab016e7517d4, content=<a href='/topic/show?id=985ee90497b' target=_blank style='color:#2F92EE;'>#维格列汀#</a>, objectTitle=维格列汀与胰岛素联合治疗伴有严重肾功能损伤的T2DM患者，其HbA1c降幅更显著, objectType=article, longId=3225, objectId=8a2b322552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a2b322552, replyNumber=0, likeNumber=78, createdTime=2011-10-23, rootId=0, userName=闆锋旦, userId=e39b27527852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a2b322552, moduleTitle=维格列汀与胰岛素联合治疗伴有严重肾功能损伤的T2DM患者，其HbA1c降幅更显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a2b322552)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

维格列汀

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#二甲双胍# #维格列汀# #2型糖尿病# #瑞格列净#

JTUMS：维格列汀和瑞格列净联合二甲双胍治疗2型糖尿病的疗效和安全性

2024-06-18发表于上海

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

.JACC Heart Failure:维格列汀对2型糖尿病合并心衰患者心室功能有何影响？

2018-08-07

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

Diabetes Care：维格列汀和二甲双胍对小肠输注葡萄糖的2型糖尿病患者血压和心率的反应有啥影响？

2017-09-25

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

母义明：维格列汀是2型糖尿病单药治疗后的又一选择？

2015-12-25

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

诺华提请禁止印度百康推出其维格列汀仿制药

2014-10-16

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

Lancet: 维格列汀首证个体化达标在老年糖尿病患者中可以实现（INTERVAL研究）

2014-04-27

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

Medpage：维格列汀对心力衰竭患者的心血管安全性尚不确定

2013-11-30

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

诺华维格列汀（佳维乐）在中国上市

2012-04-22

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

JCPT：Meta分析证实维格列汀疗效和安全性

2012-03-20

闆锋旦 (审核中...)

前往app查看评论内容

#维格列汀#

维格列汀与胰岛素联合治疗伴有严重肾功能损伤的T2DM患者，其HbA1c降幅更显著

2011-10-23

科室
- - 订阅+
  - 更多科室
工具
服务